For example, tissue-specific KOs of sAC (e.g., SMCs vs
The American Diabetes Associations Standards of Care in Diabetes2025 have recommended the use of GLP-1RAs in patients with T2DM, symptomatic heart failure with preserved ejection fraction, and obesity [40]
Vomiting: While less common than nausea, vomiting can also occur with GLP-1 receptor agonists
In the private insurance market, 57.4 million adults under 65 could be potentially eligible for GLP-1 drugs Over 2 in 5 (42%) adults under 65 with private insurance could be eligible for GLP-1 drugs, based on current Food and Drug Administration (FDA) indications
Fornes, A., Huff, J., Pritchard, R
GersteinHCColhounHMDagenaisGRDiazRLakshmananMPaisPet alDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial